新型冠状病毒肺炎药物引起获得性长QT综合征的研究进展  

Research progress about acquired long QT syndrome caused by drugs for COVID-19

作　　者：傅银 廉姜芳[2] FU Yin;LIAN Jiangfang(School of Medicine,Ningbo University,Ningbo 315211,China;不详)

机构地区：[1]宁波大学医学院,315211 [2]宁波市医疗中心李惠利医院心内科

出　　处：《心电与循环》2022年第4期311-315,330,共6页Journal of Electrocardiology and Circulation

基　　金：浙江省自然科学基金项目(LY21H020001)。

摘　　要：新型冠状病毒肺炎(COVID-19)在全球范围内不断蔓延,对全球卫生系统构成了较大挑战,全球感染及死亡人数不断上升,目前经验性使用的药物包括氯喹、羟氯喹、阿奇霉素、洛匹那韦、利托那韦、瑞德西韦、氟伏沙明等可能会导致获得性长QT综合征(a LQTS),具体表现为患者心电图QT间期延长,甚至发生危及生命的室性心律失常、尖端扭转型室性心动过速和心源性猝死,现将对目前用于治疗COVID-19药物引起a LQTS的可能性进行述评。Coronavirus disease 2019(COVID-19),caused by severe acute respiratory syndrome coronavirus 2,is a global challenge to global health,with an increasing number of infections and deaths worldwide,and empirical drugs currently used in COVID-19,including chloroquine,hydroxychloroquine,azithromycin,lopinavir,ritonavir,remdesivir,fluvoxamine and others,which may lead to acquired long QT syndrome(aLQTS),characterized by prolonged QT intervals and even life-threatening ventricular arrhythmias,such as Torsade de Pointe(TdP)and sudden cardiac death,This review summarizes the possibility of acquired long QT syndrome caused by drugs for COVID-19.

关 键 词：COVID-19 HERG通道 QT间期 获得性长 QT综合征 

分 类 号：R563.1[医药卫生—呼吸系统]